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Context. Targeted needle biopsies are increasingly performed for the genetic characterization of cancer. While the nucleic acid
content of core needle biopsies after standard pathology processing (i.e., formalin ﬁxation and paraﬃn embedding (FFPE)) has
been previously reported, little is known about the potential yield for molecular analysis at the time of biopsy sample
acquisition. Objectives. Our objective was to improve the understanding of DNA and RNA yields from commonly used core
needle biopsy techniques prior to sample processing. Methods. We performed 552 ex vivo 18 and 20G core biopsies in the lungs,
liver, and kidneys. DNA and RNA were extracted from fresh-frozen core samples and quantiﬁed for statistical comparisons
based on needle gauge, biopsy site, and tissue type. Results. Median tumor DNA yields from all 18G and 20G samples were
5880 ng and 2710 ng, respectively. Median tumor RNA yields from all 18G and 20G samples were 1100 ng and 230 ng,
respectively. A wide range of DNA and RNA quantities (1060–13,390 ng and 370–6280 ng, respectively) were acquired. Median
DNA and RNA yields from 18G needles were signiﬁcantly greater than those from 20G needles across all organs (p < 0 001).
Conclusions. Core needle biopsy techniques for cancer diagnostics yield a broad range of DNA and RNA for molecular
pathology, though quantities are greater than what has been reported for FFPE processed material. Since non-formalin-ﬁxed
DNA is advantageous for molecular studies, workﬂows that optimize core needle biopsy yield for molecular characterization
should be explored.
1. Introduction
Image-guided solid tumor needle biopsies are frequently the
starting point for modern cancer care. The ability to genomi-
cally characterize tumors has ampliﬁed the importance of
tissue biopsies for cancer treatment selection, determining
eligibility for clinical trials and understanding disease
progression. In recent years, the brisk pace of discoveries
revealing the genetic basis for malignant transformation has
empowered oncologists, enabling therapies targeting speciﬁc
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molecular aberrations [1–3]. Needle biopsies can provide
material for targeted genetic mutation analysis or to assess
response to treatment, obviating the need for surgical biopsy.
A high-quality, high-value biopsy is now deﬁned by suf-
ﬁcient cancer cellularity for diagnosis and genomic analysis
[4]. Diagnostic rates for contemporary targeted biopsies are
high, but procedural practice guidelines have been slow to
consider additional sampling requirements associated with
molecular characterization [5]. Real-time CT, ultrasound,
or MR image-guidance technologies have enabled more
accurate percutaneous sampling of smaller targets [6]. How-
ever, the quantity of genetic material that can be obtained
from small tumors is not easily deﬁned due to many factors
inﬂuencing biopsy yield, including normal tissue versus solid
tumor cellularity and variable density of tumor nuclei per
volume of tissue. Furthermore, single-site biopsies may not
suﬃciently portray intratumoral genetic heterogeneity [7].
Deoxyribonucleic acid (DNA) and ribonucleic acid
(RNA) quantities required for a combination of routine
clinical care, clinical trials, and research protocols often
vary by individual institution and clinical team. Quantities
suﬃcient for analysis will also vary in relation to the
increasing number and range of molecular tests and tech-
nical advances in tissue analytics. Furthermore, several
analyses of preanalytic factors related to tumor sequencing
have raised concerns about low DNA and RNA yields
from percutaneous tumor biopsies [8, 9].
Importantly, standard core biopsy processing in pathol-
ogy laboratories includes formalin ﬁxation and paraﬃn
embedding (FFPE). All downstream diagnostic and molecu-
lar assays are generally performed on thin sections prepared
by microtomy from FFPE tissue blocks. In most studies to
date, DNA and RNA content in core biopsies has been ana-
lyzed from FFPE material, whereas quantities of nucleic acid
in unprocessed core biopsies are not well established. The
goal of this study was to assess DNA and RNA quantities
obtained using widely used core biopsy techniques from
diﬀerent cancer types in order to facilitate planning and
decision-making with regard to molecular oncology testing.
Knowledge of needle biopsy sampling capabilities can be
essential for patient management in the setting of either
known or suspected cancer. For both patient and healthcare
provider, the anticipated value of quantitative data to plan
needle biopsies is a better understanding of the potential risk
versus clinical beneﬁt [10–12].
2. Materials and Methods
We performed an Institutional Review Board-approved pro-
spective study of surgically resected specimens at a compre-
hensive cancer center with a waiver of informed consent.
Biopsies were performed in a tissue procurement service
facility under direct visualization within 2 hours of surgical
excision using 18-gauge (18G) and 20-gauge (20G) core
biopsy needles (Temno Evolution, CareFusion, Waukegan,
IL). Each surgical specimen was ﬁrst dissected to allow direct
visualization of the tumor and surrounding normal tissues.
Biopsies were acquired from a variety of locations in normal
parenchyma and tumor, avoiding areas of visible necrosis,
and each 2 cm long core needle sampling tray was visually
inspected. Core specimens that did not ﬁll at least 85% of
the sampling tray were discarded. Biopsies were performed
in triplicate using 18G and 20G needles for both DNA and
RNA processing. Biopsy sample sizes were estimated based
on the number of samples required to achieve statistical
signiﬁcance from a preliminary kidney biopsy cohort. Each
specimen was immediately placed in a 1.7ml Eppendorf
tube and snap frozen in liquid nitrogen. Samples were
then stored in a −80°C freezer until molecular extractions
were performed.
2.1. DNA Extraction. DNA was extracted using a standard
protocol (DNeasy, Qiagen, Venlo, Netherlands) with 4μl
RNase A added immediately after incubation. 50μl of
10 nM Tris-Cl and 0.5mM EDTA buﬀer (AE, pH 9.0) were
used for the elution step.
2.2. RNA Extraction. RNA was extracted in an RNase-free
environment according to the standard product protocol
(RNeasy, Qiagen). All RNA samples were kept on dry ice
during extraction. Tissues were lysed using 1.4mm ceramic
spheres (lysing matrix D, MP Biomedicals, Solon, OH) in a
tissue homogenizer (Fast Prep 24, MP Biomedicals) and
650μl of lysis buﬀer (RLT Buﬀer, Qiagen) with the addition
of on-column DNase digestion before RNA puriﬁcation.
30μl of RNase-free water was used to elute all samples.
2.3. Quantitative Measurements. DNA and RNA quantity
(total DNA and RNA) was calculated from concentration
multiplied by volume. Concentration was measured using a
spectrophotometer (Nanodrop 2000, Thermo Scientiﬁc). If
the measured ratio of absorbance at 260 : 280 was less than
1.6 for DNA or 1.8 for RNA, the samples were run for an
additional time on the chromatography columns in the
extraction protocol until the purity threshold was reached.
2.4. Statistical Analysis. The three repeated observations for
each tumor sample were averaged into a single observation
for analysis after examining the variation of repeated obser-
vations using descriptive statistics and graphical displays.
Box plots of averaged data were generated for each tumor
separately for RNA and DNA and by needle gauge (18G
versus 20G) and tissue type (normal vs. tumor). For compar-
isons between tissue type and needle gauge, the Wilcoxon
signed-rank test for paired data was used. For comparisons
across organ sites (lung versus liver versus kidney), the
Kruskal-Wallis rank sum test was applied. A p value < 0.05
was considered statistically signiﬁcant. Analyses were con-
ducted using R software version 3.1.0 (R Core Development
Team, Vienna, Austria).
2.5. Results. A total of 552 ex vivo biopsies from 46 surgically
resected lung (n = 15), liver (n = 15), and kidney (n = 16)
specimens were performed. Table 1 indicates the number of
biopsies obtained from each organ and the ﬁnal pathologic
diagnosis for each tumor type. The quantitative yield by
organ, needle gauge, and tissue type (normal vs. tumor) is
provided for DNA and RNA in Tables 2 and 3, respectively.
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2.6. DNA Yield. For all pooled organ sites, the median DNA
yield from the larger 18G biopsy needles was signiﬁcantly
greater (p < 0 001) than that from 20G needles in both tumor
and normal tissue samples. Median DNA quantities were
greater for lung tumor samples compared to normal lung tis-
sue (18G biopsies, p < 0 001; 20G biopsies, p < 0 001). There
was no statistical diﬀerence in median DNA obtained from
normal versus tumor tissues in the liver or kidney. For all
cancer types sampled, the median DNA quantity acquired
from single-needle pass 18G and 20G core biopsies was
5880 ng (range 1060–13390ng) and 2710 ng (range 370–
6280 ng), respectively. Box plots in Figure 1 depict median
DNA content as well as interquartile ranges for each tissue
type and biopsy needle gauge.
2.7. RNA Yield. The median RNA yield from 18G needles was
also signiﬁcantly greater (p < 0 001) than that from 20G
biopsies when tumor and normal samples were pooled for
all organs. Median RNA quantities were greater for lung
tumor tissue compared to nonmalignant tissues for 18G
and 20G from the lungs (18G biopsies (p = 0 001) and
20G biopsies (p < 0 001), respectively) and liver (p = 0 012
and p = 0 002, respectively), but not from the kidney. The
median RNA quantity from 18G and 20G cancer biopsies
was 1100 ng (range 110–17210ng) and 230 ng (range 60–
5210 ng), respectively. Box plots in Figure 2 depict median
RNA quantities and interquartile range by needle gauge
and tissue type.
3. Discussion
In the recent years, cancer genetic technologies such as next-
generation sequencing (NGS) have evolved, oﬀering insights
beyond traditional histopathologic or radiographic diagnoses
[13]. Increased emphasis on molecular characterization has
highlighted the role of targeted tissue biopsies in oncology,
now routinely obtained for personalized treatment planning
and for correlative studies in clinical trials. Gene sequencing
for mutation proﬁling can be particularly challenging for
solid tumors as formalin ﬁxatives can disrupt DNA integrity
[14]. As nucleic acid yield is not enumerated at the time of
biopsy, even when on-site cytopathology review is per-
formed, it can be diﬃcult to determine whether suﬃcient
genetic material has been obtained [15].
While tumor heterogeneity, cellularity, and size as well as
other preanalytic parameters and factors can impact down-
stream analytic success, important information can be gained
from studies examining DNA and RNA yield using standard-
ized ex vivo conditions [16, 17]. Notably, one previous study
focused on lung tumor core biopsies reported no statistical
diﬀerence between in vivo and ex vivo nuclei acid yields
within cohorts of the same tumor type [17]. These same
authors also attempted to predict tissue yields from core
biopsies using needles of diﬀerent gauges used in clinical
practice with multivariate regression. A moderately strong
correlation between calculated sampling volume and nucleic
acid yield was observed, though analysis was limited to lung
tumors and a relatively small number of biopsy samples. In
this study, we examined a larger number of primary and met-
astatic tumor biopsies from the lungs, livers, and kidneys,
increasing the potential generalizability of our ﬁndings.
Only in the lung, and not in the liver or kidney, did we
observe a statistically signiﬁcant diﬀerence in DNA quanti-
ties obtained from normal parenchyma versus tumor tissues.
In this case, increased cell density, particularly relative to
normally air-ﬁlled lung tissues, and higher nuclear to cyto-
plasmic ratios may account for higher quantities of genetic
material in lung tumor samples versus normal aerated lung
[18, 19]. RNA diﬀerences were observed in the liver and lung
but not observed in the kidney. A previous study also
reported no diﬀerence in RNA content between primary
renal malignancies and normal renal parenchyma [20].
Similar to other studies, we found that larger 18G nee-
dles acquired twofold more DNA and ﬁvefold more RNA
on average compared to 20G needles, suggesting that addi-
tional needle passes may be necessary to obtain suﬃcient
genetic material when using smaller-gauge needles. The
clinical implications of substantial yield variance should
not be minimized however, as linear models have not been
validated in clinical practice, and smaller 20G needles can
eﬀectively reveal clinically meaningful mutations in lung
tumors [17, 21]. Based on our ﬁndings, the notion that one
additional large volume core needle pass will guarantee
nucleic acid sampling adequacy could lead to analytic failure.
In real-world practice, percutaneous biopsy indications,
approach, and technique must be considered to minimize
procedural morbidity and maximize eﬃcacy. In a recent
meta-analysis, the risk for complications following a lung
biopsy correlated with larger biopsy needles [22]. Prior
knowledge of minimum sampling requirements can facilitate
estimation of biopsy feasibility, safety, and likelihood of
success. In particular, the number and type of analytic studies
to be performed can inﬂuence biopsy decisions as higher
Table 1: Pathologic tissue diagnoses by organ.
Kidney ( n = 16 )
Clear cell carcinoma 13
Papillary carcinoma 1
Unclassiﬁed renal cell carcinoma 1
Chromophobe carcinoma 1





Lung ( n = 15 )
Squamous cell carcinoma 6
Lung adenocarcinoma 5
Carcinoid 1
Metastatic poorly diﬀerentiated carcinoma 1
Mucinous carcinoma 1
Lymphoma 1
Total number of specimens biopsied 46
Total biopsy samples (normal + tumor tissues) 552
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complication rates are associated with increased needle
passes and larger-gauge needles [10, 11]. Ideally, specimen
quantities would be well balanced with procedure time and
the lowest achievable patient risk.
The practical implications of this study are most apparent
in relation to contemporary genetic testing requirements and
sources of preanalytic biopsy sample variation. Minimum
DNA for NGS can vary depending upon the clinical labora-
tory technology platform, as well as the target enrichment
strategy and number of genes tested in a panel. For example,
for the NGS platform currently used at our institution—hy-
bridization capture MiSeq Illumina-based MSK-IMPACT
assay [23]—200–250 ng of DNA is optimally required.
DNA quantities as low as 10 ng may be successfully analyzed
using the Ion Torrent (Thermo Scientiﬁc, Waltham, MA)
platform [8], though sequencing errors may occur with lim-
ited DNA.
Biopsy sample RNA proﬁling is highly dependent upon
quality, as fragmentation or degradation by RNases can
hamper mutational analysis. Microarray technologies can
be used to analyze 500ng of RNA, while NGS and ampliﬁca-
tion techniques can substantially lower thresholds for clini-
cally meaningful sequencing, even to the level of single-cell
genetic material [24, 25].
Table 2: Median DNA (range) from 18- versus 20-gauge needle samples from normal and tumor tissues obtained from the kidney,
lung, and liver.
18G biopsy (ng DNA) 20G biopsy (ng DNA) p value (18G vs. 20G)
Any organ
Normal 4350 (1730, 13040) 1970 (700, 5620) <0.001
Tumor 5880 (1060, 13390) 2710 (370, 6280) <0.001
Kidney
Normal 4150 (1930, 11890) 1360 (700, 3870) <0.001
Tumor 3170 (1180, 13390) 1450 (370, 4600) <0.001
p value (normal vs. tumor) 1.00 0.890
Lung
Normal 3240 (1740, 13040) 1720 (760, 3520) <0.001
Tumor 6910 (3070, 12570) 3350 (1110, 6280) <0.001
p value (normal vs. tumor) <0.001 <0.001
Liver
Normal 6050 (3790, 9740) 2480 (1890, 5620) <0.001
Tumor 6190 (1060, 11530) 2630 (480, 5160) <0.001
p value (normal vs. tumor) 0.804 0.847
Table 3: Median RNA (range) from 18- versus 20-gauge needle samples from normal and tumor tissues obtained from the kidney, lung,
and liver.
18G biopsy (ng RNA) 20G biopsy (ng RNA) p value (18G vs. 20G)
Any organ
Normal 510 (30, 23540) 240 (30, 7090) <0.001
Tumor 1100 (110, 17210) 230 (60, 5210) <0.001a
Kidney
Normal 480 (230, 1210) 270 (110, 460) <0.001
Tumor 510 (220, 3420) 290 (70, 2480) <0.001
p value (normal vs. tumor) 0.855 0.217
Lung
Normal 150 (30, 4940) 120 (30, 400) 0.008
Tumor 2870 (170, 12700) 290 (70, 2480) <0.001
p value (normal vs. tumor) <0.001 <0.001
Liver
Normal 4740 (60, 23540) 700 (60, 7090) <0.001
Tumor 1190 (110, 17210) 150 (60, 5210) <0.001
p value (normal vs. tumor) 0.012 0.002
aExact test could not be performed due to ties, normal approximation used.
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Assuming no degradation, fragmentation, or other prea-
nalytic disruption of biopsy samples, based on the median
DNA content revealed in this study, a single 2 cm long 18G
or 20G biopsy should be suﬃcient for most contemporary
NGS assays. The same holds true for RNA; however, at the
lower end of the RNA range, as low as 60ng for 20G core nee-
dle biopsies, a single biopsy sample may be more susceptible
to analytic failure. In practice, sample degradation and
disruption do occur during acquisition and processing. The
routine ﬁxation methods fail to conserve the structure of
nucleic acids and proteins in tissues. Even short-term treat-
ment of sections with formalin has been shown to signiﬁ-
cantly reduce the DNA solubility. Similarly, the extraction
of useful RNA from FFPE tissue is often compromised
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Figure 1: DNA content by tissue type and needle gauge in (a) lung tumors, (b) liver tumors, and (c) kidney tumors (N18 = normal tissue/18
gauge, T18 = tumor tissue/18 gauge, N20 = normal tissue/20 gauge, and T20 = tumor tissues/20 gauge). The dark bar represents median DNA























Figure 2: Logarithmic scale of RNA content by tissue type and needle gauge in (a) lung tumors, (b) liver tumors, and (c) kidney tumors
(N18 = normal tissue/18 gauge, T18 = tumor tissue/18 gauge, N20 = normal tissue/20 gauge, T20 = tumor tissues/20 gauge). The dark bar is
the median, the box encompasses the 25–75 interquartile range (IQR), the dotted brackets are 1.5∗IQR, and dots are outliers.
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because of incomplete lysis leading to poor extraction eﬃ-
ciency. In a recent study, RNA extracted from FFPE samples
was severely degraded compared to fresh-frozen samples
[26]. In our results, the DNA and RNA yield prior to sample
processing was 4–6-fold greater than what has previously
been reported for FFPE cell blocks [27]. Our results reveal
unprocessed nucleic acid yield from core biopsies, which
can be frozen at the point of acquisition and submitted
for DNA sequencing without FFPE. The potential limita-
tion of this approach is that direct molecular characteriza-
tion without histopathologic conﬁrmation could result in
unconstructive processing of nontumor tissues. Therefore,
workﬂows that increase tumor yield from biopsies, such
as radiographic image guidance to conﬁrm needle position
within tumor tissues, could mitigate this limitation. Ongo-
ing work suggests that transmission optical spectroscopy
imaging of fresh core samples can rapidly characterize
tissues at the point of acquisition, which could be used
to select appropriate samples for ﬂash freezing prior to
molecular diagnostic assays [28].
Although the biopsy yields reported here can serve as a
reference for physicians planning or performing molecular
studies, the following limitations must be considered in
regard to the generalizability of our data. Many factors
may reduce the quantity of RNA and DNA suitable for
analysis within a small solid tumor biopsy sample, including
prior chemotherapy [29] or tumor-associated desmoplasia
[30, 31]. In addition, necrotic tissue has a lower cellular con-
tent and can adversely impact biopsy eﬃcacy, even when
molecular studies are not planned [32, 33]. While each
biopsy was visually screened for a minimum tissue sample
length, we did not examine tissues at the microscopic level
for cellular composition. We selected tumors that were large
enough to ﬁll a 2 cm core needle biopsy sampling tray. As
increased tumor size is associated with increased necrosis
[34], we cannot be certain that molecular quantities reported
here are valid for larger tumors. By the same token, we
cannot certify based on these data that tumors smaller
than 2 cm will contain less genetic material in linear propor-
tion to biopsy sample length. We also used common
spectroscopy-based techniques to quantify the molecular
content of biopsy samples; however, these types of measure-
ments can result in overestimations. Decreased accuracy is
attributed to poor 260 : 280nm absorption ratios and cross-
contamination of RNA and DNA [35]. We used recom-
mended extraction protocols to remove DNA or RNA
contaminants; however, remaining contaminants could have
inﬂuenced yield. Finally, due to the wide variation in the
operator technique impacting sampling volumes, we did
not study common alternative needle biopsy methods such
as ﬁne-needle aspiration.
In summary, we report a wide range of nucleic acid
quantities obtained from core needle biopsies in organs
commonly aﬄicted with primary or metastatic cancer.
Overall, unprocessed sample nucleic acid quantities are
increased relative to FFPE processed tissues; therefore,
workﬂows that bypass ﬁxation and paraﬃn-based process-
ing may improve yield and utility of core needle sampling
for molecular diagnostics.
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